New and different “home” where scientific inventors can transform their visions into cell and gene therapies for patients with devastating diseases
The right combination of scientists, operators, leaders, and backers to launch and build multiple companies in multiple cell and gene therapy treatments
BaseCamp is a new business model to marshal and manage all resources needed to translate lab science to the patient’s bedside
AlloVir is tackling one of the most challenging complications for patients who have undergone hematopoietic stem cell transplantation, fighting off life-threatening or life-altering viral diseases.
HighPass is taking a new approach, known as adoptive T-cell therapy, to research treatments and preventions for relapsing leukemia, which affects 25-50% of patients who have undergone HSCT to treat their cancer.
One of the nation’s leading hospitals, Massachusetts General Hospital (MGH) is partnering with ElevateBio to accelerate the development of cell and gene therapies for clinical trials run at, and by, MGH innovators.
The strategic partnership gives MGH preferred access to ElevateBio’s BaseCamp research, process development, and manufacturing facility. ElevateBio will support a variety of MGH’s cell and gene therapy research programs. Our organizations will work together to identify cell and gene technologies and create therapeutics companies.
We’re pioneering new methods to develop next generation, cell, viral, and regenerative therapies. We offer expertise to our portfolio companies and partners to accelerate the development of cell and gene therapies, from cGMP manufacturing suites to protein engineering, virology, and immunology labs.
Together with scientific innovators and our strategic partners, we are rapidly building a diverse portfolio of companies.
